Physician profile
David E Hammond
NPI 1972669083
$836.37
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $287.41 | 2019 | |
| Celgene Corporation | $257.10 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.18 | 2019 | |
| Sun Pharmaceutical Industries INC. | $47.69 | 2019 | |
| Genzyme Corporation | $30.43 | 2019 | |
| Ucb, INC. | $30.04 | 2019 | |
| Janssen Biotech, INC. | $25.61 | 2019 | |
| Lilly USA, LLC | $17.98 | 2019 | |
| Mayne Pharma Commercial LLC | $17.73 | 2019 | |
| Merck Sharp & Dohme LLC | $12.34 | 2019 | |
| Almirall LLC | $10.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.